logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2018 – Longer survival adding bortezomib instead of vincristine in transplantation-ineligible patients with mantle-cell lymphoma

Despite high haematological toxicity, frontline therapy adding bortezomib improved overall survival over vincristine-based treatment in transplant-ineligible patients with newly diagnosed mantle cell lymphoma